Medical University of South Carolina

PI Name

Institutional Biosafety Committee Meeting Minutes

Meeting Date	Thursday, July 10, 2025		
Meeting Time	12:04 PM – 2:02 PM		
Meeting Type	Teams Meeting		
IBC Members Present	1. Caroline Westwater, Ph.D., (IBC Chair) 2. John Woodward, Ph.D. (IBC Vice Chair) 3. Christina Voelkel-Johnson, Ph.D., (BSO) 4. Arabinda Das, Ph.D., (IBC Member) 5. Lisa Steed, Ph.D., (IBC Member) 6. Alicia Braxton Hickman, DVM, Ph.D., DACLAM (IBC Member / Veterinary Medical Officer) 7. Diane Lauritsen, Ph.D., (Local Non-affiliated Member) 8. Ana Zimmerman, Ph.D. (Local Non-affiliated Member)		
Quorum	Number of Members Present (Voting):8 Number of Members Not Present:2 Late Arrival of Voting Members:0 Early Departure of Voting Members:0		
Other Individuals in Attendance	Michael Smith, Ph.D., (IBC Manager) Gloriane Schnabolk Ph.D., (IACUC & IBC Senior Administrator)		
Call to Order	The IBC Chair called the meeting to order at 12:04 PM		
Conflicts of Interests	The IBC Chair reminded all members present to identify any conflicts of interest before each registration is reviewed.		
Review and Approval of Previous Meeting Minutes	Date of meeting minutes approved: May 8, 2025 Motion to approve the minutes as written. Voting: (Total =8, For =8, Opposed =0, Abstain = 0).		
Review of Prior Business	Discussed the development of a RedCap self- assessment form for compliance with the Executive Order of May 5, 2025. Discussed NOT-OD-25-082: Promoting Maximal Transparency Under the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules		
New IBC Registration and Amendme	ents for Review (repeat for each registration)		

Protocol # IBC-25-253

Yao, Hai

Formatted: Font: 11 pt, Font color: Auto

Study Title	Establishment of Stable Fluorescently Labeled Cell Lines for Visualization and Tracking of Mitochondrial Transfer Between Chondrocytes and Endothelial Cells			
Agent	Chondrocytes and Endothelial Cells Plasmid DNA/mRNA CRISPR/Cas9 technology Molecular grade Escherichia coli Laboratory grade strains Saccharomyces cerevisiae Replication-deficient viral vectors RG1 microbes RG2 microbes Biological toxins Gene modified mouse cells Gene modified human cells			
	☐ Other			
rDNA Category	III-D1a			
Genetically modified microbes or vectors	Lentiviral vector			
Transgene expression	mito-Dendra2, mCherry			
Highest BSL	BSL2			
Training		ndina		
Risk Assessment of	PPE is appropriate	for 🗍 BSL1 🛛 BSL2 🗌	ABSL1 ☐ ABSL2	
Procedures	Waste handling: ☑ Chemical inactivation ☑ Physical inactivation Aerosol handling: N/A ☐ Yes ☑ BSC Centrifugation: N/A ☐ Sealed rotors/safety caps ☑ Sharps handling: N/A ☑ Standard sharps precautions ☐ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☑ Any special considerations No ☑ Yes ☐			
Motion	Straight approval Conditional approval with administrative post-review Conditional approval with subcommittee post-review			
First:	Voelkel-Johnson	Second:	Westwater	
Votes				
For:8	Against:0	Abstained:0	Recused:0	
Protocol #	IBC 25 261			
Protocol #	IBC-25-261			
Study Title	, -	Hartman, Jessica Generating CRISPR/Cas9-edited CYP2E1-flox and KO mice with		
	MIC TOL COIC			

Protocol #	IBC-25-261
PI Name	Hartman, Jessica
Study Title	Generating CRISPR/Cas9-edited CYP2E1-flox and KO mice with
	the TGE Core
Agent	☐ Plasmid DNA/mRNA
	□ CRISPR/Cas9 technology
	☐ Molecular grade Escherichia coli
	☐ Laboratory grade strains Saccharomyces cerevisiae
	Replication-deficient viral vectors
	RG1 microbes

	RG2 microbes			
	Biological toxins			
	Gene modified mouse cells			
	Gene modified human cells			
DNA CALAMA	☐ Other			
rDNA Category	III-D4b, III-E-3			
Genetically modified	N/A			
microbes or vectors				
Transgene expression	Cyp2E1			
Highest BSL	BSL1, ABSL1			
Training		nding		
Risk Assessment of	PPE is appropriate f	for 🛛 BSL1 🗌 BSL2 🖂] ABSL1 □ ABSL2	
Procedures		Chemical inactivation [>	Physical inactivation	
	Aerosol handling: N			
		$\boxtimes \underline{S}$ ealed rotors/safety		
		A 🗌 Standard sharps p		
		ouble sealed, durable le	eak-proof container with	
	biohazard label 🛚			
	Any special conside	rations No 🛛 Yes 🗌		
Motion	Straight approva			
		oval with administrative		
E		oval with subcommittee		
First:	Westwater	Second:	Woodward	
Votes	A : 10	AL 1 . 10	D 10	
For:8	Against:0	Abstained:0	Recused:0	
Protocol #	IBC-25-260			
PI Name	Patterson, Logan			
Study Title		ry Specimens Biobankin	q	
Agent	Plasmid DNA/mF			
	CRISPR/Cas9 te	chnology		
	Molecular grade	Escherichia coli		
		e strains Saccharomyces	s cerevisiae	
	Replication-defic	ient viral vectors		
	RG1 microbes			
	RG2 microbes			
	☐ Biological toxins			
	Gene modified mouse cells			
	Gene modified h			
	Other: RG2 bact	erial isolates		
rDNA Category	N/A			
Genetically modified	N/A			
microbes or vectors	l .			

Transgene expression	N/A			
Highest BSL	BSL2			
Training	Complete Per	nding		
Risk Assessment of	PPE is appropriate f	for 🗍 BSL1 🔀 BSL2 🗌	ABSL1 ABSL2	
Procedures	Waste handling:	Chemical inactivation	Physical inactivation	
	Aerosol handling: N	/A ⊠ Yes □	-	
		⊠ Sealed rotors/safety		
	Sharps handling: N/A ☐ Standard sharps precautions ☒			
		ouble sealed, durable le	ak-proof container with	
	biohazard label 🛚			
	Any special conside	rations No 🛛 Yes 🗌		
BA - 41		1		
Motion	Straight approva			
		oval with administrative oval with subcommittee		
First:	Westwater	Second:	Woodward	
Votes	vvestwater	oecona.	VVOOdWald	
For:7	Against:0	Abstained:1	Recused:0	
1 01.7	/ tgainotto	7 tootamod. 1	11000000.0	
	T -			
Protocol #	IBC-25-245			
PI Name	Jiang, Wei			
Study Title	Investigating HIV pathogenesis using EcoHIV infected mice			
Agent	Plasmid DNA/mRNA			
	CRISPR/Cas9 technology Molecular grade Escherichia coli			
			o corovinio	
	Laboratory grade strains Saccharomyces cerevisiae Replication-deficient viral vectors			
	RG1 microbes	ieni viiai veciois		
	RG2 microbes			
	Biological toxins			
	Gene modified m	nouse cells		
	Gene modified h	uman cells		
	Other			
rDNA Category	III-D1a, III-D4b			
Genetically modified	EcoHIV			
microbes or vectors				
Transgene expression	MLV gp80, GFP, luciferase			
Highest BSL	BSL2, ABSL2	P		
Training	Complete Per		LABOLA TABOLA	
Risk Assessment of		for BSL1 BSL2		
Procedures	vvaste handling:	Chemical inactivation	I Physical inactivation	
	Aerosol handling: N		oone M	
		Sealed rotors/safety		
	onarps nanding: N/	A 🗌 Standard sharps p	coautions 🖂	

	Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐				
Motion	Conditional appr	☐ Straight approval ☐ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review			
First:	Steed	Second:	Westwater		
Votes					
For:8	Against:0	Abstained:0	Recused:0		
Protocol #	IBC-25-244				
PI Name	Carroll, Steven				
Study Title	Comparative Oncoger Discovery	nomics for Peripheral	Nerve Sheath Cancer Gene		
Agent	 ☑ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☑ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☑ Gene modified mouse cells ☑ Gene modified human cells ☐ Other 				
rDNA Category	III-D1a, III-D4b				
Genetically modified	Adenoviral and Len	tiviral vectors			
microbes or vectors					
Transgene expression	Cre recombinase, H2B-mCherry, bTubulin-EYFP, Erbb4 p.lle712Met and Erbb4 p.Arg927Gln, VCP, NF1, GFP				
Highest BSL	BSL2, ABSL2				
Training	□ Complete □ Pending				
Risk Assessment of Procedures	PPE is appropriate for BSL1 BSL2 ABSL1 ABSL2 Waste handling: Chemical inactivation Physical inactivation Aerosol handling: N/A Yes Centrifugation: N/A Sealed rotors/safety caps Sharps handling: N/A Standard sharps precautions Transport: N/A Double sealed, durable leak-proof container with biohazard label Any special considerations No Yes				
Mation	Ctual what a more con-	1			
Motion	☐ Straight approval ☐ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review				

First:	Voelkel-Johnson	Second:	Westwater
Votes			
For:8	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-268			
PI Name	Tsao, Betty			
Study Title	Generating with TGE core			
Agent	 ☑ Plasmid DNA/mRNA ☑ CRISPR/Cas9 technology ☑ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other 			
rDNA Category	III-D1a, III-E-3			
Genetically modified microbes or vectors	N/A			
Transgene expression	Slc7a7			
Highest BSL	BSL1, ABSL1			
Training				
Risk Assessment of Procedures	PPE is appropriate for BSL1 BSL2 ABSL1 ABSL2 Waste handling: Chemical inactivation Physical inactivation Aerosol handling: N/A Yes Centrifugation: N/A Sealed rotors/safety caps Sharps handling: N/A Standard sharps precautions Transport: N/A Double sealed, durable leak-proof container with biohazard label Any special considerations No Yes			
Motion	Straight approval Conditional approval with administrative post-review Conditional approval with subcommittee post-review			
First:	Woodward	Second:	Westwater	
Votes				
For:8	Against:0	Abstained:0	Recused:0	

Protocol #	IBC-25-266
PI Name	Zhai, Yuan
Study Title	Liver Immune Responses against Ischemia-Reperfusion
Agent	☐ Plasmid DNA/mRNA

	CRISPR/Cas9 te	echnology	
	☐ Molecular grade	Escherichia coli	
	Laboratory grade	e strains Saccharomyce	s cerevisiae
	Replication-defic	cient viral vectors	
	☐ RG1 microbes		
	☐ RG2 microbes		
	Biological toxins		
	Gene modified n	nouse cells	
	Gene modified h		
	Other		
rDNA Category	N/A		
Genetically modified	N/A		
microbes or vectors			
Transgene expression	N/A		
Highest BSL	BSL2, ABSL2	ndina	
Training	Complete Pe	naing for 🗌 BSL1 🔀 BSL2 🗀	
Risk Assessment of Procedures	PPE is appropriate	for ☐ BSL1 ☒ BSL2 ☐ Chemical inactivation ☐	ABSL1 🖂 ABSL2
Procedures	Aerosol handling: N		_ Priysical mactivation
	Contributed in N/A	Sealed rotors/safety	
	Centrilugation: N/A	Sealed folors/salety	caps
	Transport N/A	A ☐ Standard sharps pouble sealed, durable le	recautions 🖂
		ouble sealed, durable le	eak-proof container with
	biohazard label	matiana Na 🏻 Vaa 🗖	
	Any special considerations No ⊠ Yes □		
Motion			
Motion	Straight approva		maat marriare
		oval with administrative	
Finate		oval with subcommittee	
First:	Voelkel-Johnson	Second:	Das
Votes		41 4 : 10	-
For:8	Against:0	Abstained:0	Recused:0
Protocol #	IBC-25-262		
PI Name	Smith, Alexander		
Study Title	Discovery of novel p	oharmacotherapeutic tar	gets for opioid
	addiction	•	
Agent			
	CRISPR/Cas9 te	echnology	
	Molecular grade		
		e strains Saccharomyce	s cerevisiae
	Replication-defic		
	RG1 microbes		
	RG2 microbes		
1			
	☐ Biological toxins☐ Gene modified m	nouse cells	

	Other			
rDNA Category	I III-D1a, III-D4b			
Genetically modified	AAV			
microbes or vectors				
Transgene expression	ChR2, eNpHR, EYF recombinase	FP/mCherry/GCaMP, Cre	recombinase, Flp	
Highest BSL	BSL2, ABSL2			
Training		nding		
Risk Assessment of	PPE is appropriate	for 🗍 BSL1 🛛 BSL2 🗌	ABSL1 ⊠ ABSL2	
Procedures	Waste handling:	Chemical inactivation		
	Aerosol handling: N		•	
	Centrifugation: N/A	Sealed rotors/safety ←	caps 🗌	
		/A Standard sharps p		
		ouble sealed, durable le	ak-proof container with	
	biohazard label 🛚			
	Any special conside	erations No 🛛 Yes 🗌		
Mation	Ctualet	.1		
Motion	Straight approva			
	Conditional appr	oval with administrative oval with subcommittee	post-review	
Final				
First:	Woodward	Second:	Westwater	
Votes	A : 10	41 1 : 10	D 10	
For:8	Against:0	Abstained:0	Recused:0	
Protocol #	IBC-25-258			
PI Name	Mei, Ying			
Study Title		sitory, Ying Mei, Serum a	nd Blood samples	
Agent	☐ Plasmid DNA/ml		,	
	CRISPR/Cas9 to			
	☐ Molecular grade			
		e strains Saccharomyces	s cerevisiae	
		cient viral vectors		
	RG1 microbes			
	RG2 microbes			
	Biological toxins			
	Gene modified mouse cells			
	Gene modified human cells			
rDNA Cotogogy	Other: human-derived substances/patient samples			
rDNA Category Genetically modified	N/A			
microbes or vectors	N/A			
iniciones of vectors				
Transgene expression	N/A			
	DOI 0			
Highest BSL	BSL2	ı.		
Training		nding		

Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☐ BSL2 ☐ ABSL1 ☐ ABSL2 Waste handling: ☐ Chemical inactivation ☐ Physical inactivation Aerosol handling: N/A ☐ Yes ☐ Centrifugation: N/A ☐ Sealed rotors/safety caps ☐ Sharps handling: N/A ☐ Standard sharps precautions ☐ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☐ Any special considerations No ☐ Yes ☐		
Motion	Straight approva	I	
Motion	□ Conditional appr	oval with administrative poval with subcommittee	
First:	Westwater	Second:	Voelkel-Johnson
Votes			
For:8	Against:0	Abstained:0	Recused:0
Protocol #	IBC-25-242		
PI Name	Zhang, Hailong		
Study Title		and Toxins in Murine In	fection Models
Agent	☐ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other		
rDNA Category	III-D1a, III-D4b		
Genetically modified	Salmonella Typhimurium, Listeria monocytogenes, Vibrio cholerae:		
microbes or vectors Transgene expression	Cholera toxin, Citrobacter rodentium: GFP		
Highest BSL	BSL2		
Training	□ Complete □ Pending		
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☐ BSL2 ☐ ABSL1 ☐ ABSL2 Waste handling: ☐ Chemical inactivation ☐ Physical inactivation Aerosol handling: N/A ☐ Yes ☐ Centrifugation: N/A ☐ Sealed rotors/safety caps ☐ Sharps handling: N/A ☐ Standard sharps precautions ☐ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☐ Any special considerations No ☐ Yes ☐		

Motion	☐ Straight approval ☐ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Westwater	Second:	Steed
Votes			
For:8	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-262		
PI Name	Han, Lu		
Study Title	Interactions between tumor cells and stromal cells		
Agent			
rDNA Category	III-D1a, III-D4b		
Genetically modified microbes or vectors	Lentiviral vector		
Transgene expression	GATA6, FOXF1, and FOXF2. Luciferase		
Highest BSL	BSL2, ABSL2		
Training			
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☐ BSL2 ☐ ABSL1 ☐ ABSL2 Waste handling: ☐ Chemical inactivation ☐ Physical inactivation Aerosol handling: N/A ☐ Yes ☐ Centrifugation: N/A ☐ Sealed rotors/safety caps ☐ Sharps handling: N/A ☐ Standard sharps precautions ☐ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☐ Any special considerations No ☐ Yes ☐		
Motion	☐ Straight approval ☐ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Westwater	Second:	Zimmerman
Votes			
For:8	Against:0	Abstained:0	Recused:0

Meeting Adjournment	The IBC Chair called for the meeting to be
	adjourned at 2:02 PM